Eye Scan Predicts MS Worsening Earlier — A New Test

Credibility

Interest

Share:2 min read

Key Takeaway

Adding a simple eye scan that measures retinal thinning to the usual MS check-up helps predict who is more likely to get worse over the next few years.

What They Found

Researchers followed people with relapsing MS who started or changed medicines and gave them brain scans and special eye scans called OCT at the start and after one year. OCT (optical coherence tomography) is like an ultrasound for the eye that uses light to measure thin layers of nerve tissue at the back of the eye; thinning there can mean nerve damage. The usual score doctors use (NEDA-3) looks for no relapses, no new MRI lesions, and no disability increase, but it did not predict later worsening well on its own. When the team added retinal thinning from the OCT to the NEDA-3 score, people flagged by this combined measure were much more likely to have disability worsen later. In short, eye layer thinning picked up ongoing nerve loss even when inflammation signs on MRI and relapses were quiet, and this predicted future disability better than NEDA-3 alone.

Who Should Care and Why

People with MS and their caregivers should care because the eye scan is quick, painless, and can find nerve damage that other tests might miss—like checking a car’s hidden engine wear when the dash lights are off. Neurologists and clinics can use this extra information to decide if a treatment needs to be changed sooner, which might help prevent more disability later. Patients on treatment who seem stable by usual checks might still have silent nerve loss detectable by OCT, so this could change follow-up plans or monitoring frequency. Caregivers can use the results to better plan daily help, rehab, or activity changes if the scan shows thinning. Overall, adding OCT helps find people at higher risk so they can get attention earlier instead of waiting for obvious worsening.

Important Considerations

This study looked at a modest number of patients and followed them for a few years, so results should be confirmed in larger groups before changing care for everyone. The eye scan flags risk but does not prove exactly what will help; doctors still need to decide if and how to change treatment based on the full picture. Also, retinal thinning can have other causes, so a doctor must interpret OCT results alongside clinical exams and tests.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Progression MS Diagnostics Clinical Trials

Article Topics:

DisabilityMultiple sclerosisNo evidence of disease activityOptical coherence tomographyProgression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News